Standalone Unaudited Financial Results for the Quarter ended on 30th June, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals reported Q1 FY26 revenue from operations of Rs. 3552.68 lacs, up about 9.2% year-on-year from Rs. 3253.57 lacs in Q1 FY25, but down from Rs. 4104.69 lacs in the preceding quarter (Q4 FY25). Total income stood at Rs. 3758.39 lacs versus Rs. 3394.14 lacs a year ago. Profit after tax rose modestly to Rs. 779.18 lacs (from Rs. 741.60 lacs, ~5% growth), translating to an EPS of Rs. 17.66 (vs Rs. 16.80). Operating costs grew faster than revenue — other expenses surged ~32% YoY to Rs. 833.11 lacs and depreciation rose ~39% to Rs. 72.25 lacs — squeezing operating margins. The auditor (D.R. Mehta & Associates) issued an unmodified limited review report.
Soft top-line growth and sharper cost inflation may weigh on near-term profitability, but steady double-digit PAT margin and clean audit keep fundamentals stable. Watch for margin recovery in coming quarters before turning constructive.